GlobeNewswire Inc.··NaTevogen Bio Advances Long COVID Therapy With Expanded HLA Coverage and Digital Care Platform
Tevogen Bio ($TVGN) expands T-cell therapy coverage to 65% of U.S. population and pursues digital care platform acquisition to advance Long COVID treatment.
TVGNTVGNWclinical trialprecision medicine